drugset / Trial / NCT04886765
A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma
Phase 1/2
Unknown
238 enrolled
AlaMab Therapeutics (Shanghai) Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This is a phase I / II, multi-center, single-arm, open-label study to evaluate the safety and efficacy of ALMB-0168 in patients with osteosarcoma whose prior standard treatment have failed.
Timeline
- Start
- 2021-05
- Primary completion
- 2023-11
- Completion
- 2024-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALMB-0168 | Unknown | — | Intravenous |